Valion Bio, Inc.
Moat Score — Valion Bio, Inc.
Total Moat Score
3 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | ClearUP's FDA clearance and proprietary nerve-targeting algorithms, plus the Entolimod license's existing FDA Fast Track and Orphan Drug designations, give Valion Bio real regulatory and IP assets well beyond what a typical pre-revenue company of its size holds. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | With only seven full-time employees and off-the-shelf, largely China-sourced components for ClearUP, Valion Bio has no cost advantage over larger device or biologics competitors — its lean structure is a survival necessity, not a competitive weapon. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | ClearUP is a small-share, cash-pay product competing against cheap over-the-counter remedies, and neither ncVNS nor Entolimod has reached commercialization, so the company has essentially no demonstrated pricing power today. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | None of Valion Bio's three programs exhibit a network effect; a ClearUP buyer's experience does not improve as more units sell. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 0 / 5 | ClearUP customers can freely switch to decongestants or steroid sprays with no lock-in, and neither ncVNS nor Entolimod has reached the market where switching costs could even be established. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 0 / 5 | The OTC sinus-relief category, the neurostimulation market, and the radiation-countermeasure market are all large enough to support far bigger, better-funded competitors, so Valion Bio's small scale offers it no structural protection. |